Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab ± Olaparib as a First-Line Treatment for Newly Diagnosed Advanced or Recurrent Endometrial Cancer: Results From the Phase III DUO-E/GOG-3041/ENGOT-EN10 Trial

News
Video

Shannon Westin, MD, reviews the results of the Phase III DUO-E/GOG-3041/ENGOT-EN10 trial in patients with newly diagnosed advanced or recurrent endometrial cancer.

Related Videos
John Paul Diaz, MD
Keiichi Fujiwara, MD, PhD, Saitama Medical University International Medical Center
PAOLA-1: A Review of Progression-Free Survival and 5-Year Follow-up Overall Survival Analysis: Exploratory Post-Hoc Analysis by Clinical Risk of Relapse
Ramez N. Eskander, MD
Abdulrahman Sinno, MD
Amin Nassar, MD
Rebecca L. Porter, MD, PhD
Related Content
FDA

FDA Approves Tisotumab Vedotin for Recurrent or Metastatic Cervical Cancer

April 29th 2024
Article
Bradley J. Monk, MD, FACOG, FACS; Paolo Tarantino, MD

Monk and Tarantino Describe the Investigation of B7-H4 Vedotin–Directed ADCs in Gynecologic and Breast Cancers

January 11th 2024
Podcast
Jharna M. Patel, MD

ChatGPT Displays Potential for Genetic Counseling in Gynecologic Oncology

April 24th 2024
Article
R. Wendel Naumann, MD

Naumann Discusses Notable Research Efforts in Endometrial Cancer

October 26th 2023
Podcast
Idalid Franco, MD, MPH, director of Equity Access and Inclusion in the Department of Radiation Oncology at Brigham and Women’s Hospital and an instructor at Harvard Medical School, both in Boston, Massachusetts

Navigating the Intersection of Radiation Therapy and Immunotherapy in Endometrial Cancer

April 20th 2024
Article
Abdulrahman Sinno, MD

Sinno Spotlights Key Clinical Trials Driving Targeted Approaches in Gynecologic Oncology

April 17th 2024
Article